BAMCO Inc
LGND icon

BAMCO Inc’s Ligand Pharmaceuticals LGND Stock Holding History

BAMCO Inc’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-797
Closed -$57K – 362
2019
Q2 		$57K Sell
797
-2,372
-75% -$175K ﹤0.01% 350
2019
Q1 		$249K Buy
+3,169
New +$240K ﹤0.01% 312

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

BAMCO Inc's LGND Position: Q3 2019 in Review

BAMCO Inc sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 797 shares — an estimated $57K sold.

BAMCO Inc first reported a position in LGND in Q1 2019 and held it in 2 quarters. The position peaked at $249K in Q1 2019. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

  • BAMCO Inc reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • BAMCO Inc sold 797 Ligand Pharmaceuticals shares in Q3 2019, an estimated $57K.
  • BAMCO Inc first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • BAMCO Inc's Ligand Pharmaceuticals position peaked at $249K in Q1 2019.
  • 275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on BAMCO Inc's 13F filing for Q3 2019, filed 14 Nov 2019.